Patent: 10,066,017
✉ Email this page to a colleague
Summary for Patent: 10,066,017
Title: | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist |
Abstract: | The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof. |
Inventor(s): | Mannent; Leda (Paris, FR), Pirozzi; Gianluca (Bridgewater, NJ), Swanson; Brian (Bridgewater, NJ), Radin; Allen (New York, NY), Gandhi; Namita A. (New York, NY), Evans; Robert (New York, NY), Hamilton; Jennifer (Hopewell Junction, NY) |
Assignee: | SANOFI BIOTECHNOLOGY (Paris, FR) REGENERON PHARMACEUTICALS, INC (Tarrytown, NY) |
Application Number: | 14/940,431 |
Patent Claims: | see list of patent claims |
Details for Patent 10,066,017
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 03/28/2017 | ⤷ Try a Trial | 2034-11-14 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 10/19/2018 | ⤷ Try a Trial | 2034-11-14 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 06/18/2020 | ⤷ Try a Trial | 2034-11-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |